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The 1.1 A˚ Crystal Structure of Human TGF-
Type II Receptor Ligand Binding Domain
forming a heterodimer capable of recruiting and activat-
ing the type I receptor (TBRI). In the absence of TBRII,
TGF- has no affinity for TBRI. Activin and MIS also use
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1Structural Biology Section this sequential mode of binding. BMP-2, BMP-7, GDF-5,
and Dpp, however, use a cooperative mode of binding.Laboratory of Immunogenetics
National Institute of Allergy and Infectious Diseases In this second binding mode, the ligand has a low affinity
for both the type I and type II receptors when expressedNational Institutes of Health
Rockville, Maryland 20852 separately, but a high affinity when expressed together.
Upon complex formation, the constitutively active ser-2 Johns Hopkins University School of Medicine
Baltimore, Maryland 21205 ine/threonine kinase in the cytoplasmic domain of TBRII
phosphorylates the kinase domain of TBRI, thereby ini-
tiating a signaling cascade through the SMAD molecules
[1, 3].Summary
TGF- exists in five different isoforms that share 66%–
80% sequence identity. Forms 1–3 are found in human,Transforming growth factor  (TGF-) is involved in a
wide range of biological functions including develop- while forms 4 and 5 are found in chicken and Xenopus,
respectively. The growth factor is expressed with an N-ter-ment, carcinogenesis, and immune regulation. Here
we report the 1.1 A˚ resolution crystal structure of hu- minal latent peptide that is cleaved to release the 112
residue mature TGF-. X-ray structure determinationman TGF- type II receptor ectodomain (TBRII). The
overall structure of TBRII is similar to that of activin has demonstrated that TGF- forms a disulfide-bonded
homodimer having a cysteine-knot structure [4–8].type II receptor ectodomain (ActRII) and bone morpho-
genic protein receptor type IA (BRIA). It displays a TBRII is a type I transmembrane glycoprotein con-
taining a 136 residue TGF- binding domain, a singlethree-finger toxin fold with fingers formed by the 
strand pairs 1-2, 3-4, and 5-6. The first finger transmembrane region, and an intracellular kinase do-
main [9]. The TGF- binding domain contains 12 cys-in the TBRII is significantly longer than in ActRII and
BRIA and folds tightly between the second finger and teine residues. The structure of the murine ActRII extra-
cellular domain [10] and a complex between humanthe C terminus. Surface charge distributions and hy-
drophobic patches predict potential TBRII binding sites. BMP-2 and its type I receptor extracellular domain [11]
show that both receptors have a three-finger toxin fold,
similar to some snake venom neurotoxins.Introduction
Here we report the structure of TBRII ectodomain at
1.1 A˚ resolution. The analysis of TBRII structure andTransforming growth factor  (TGF-) is found in most
eukaryotic organisms including C. elegans, Drosophila, its comparison to previously determined structures of
ActRII and BRIA allow us to make predictions aboutXenopus, mice, and humans. It is expressed by virtually
every cell type in most stages of development and is probable folding of other members of the TGF- recep-
tor superfamily. In addition, surface charge distributionsinvolved in a wide range of biological functions including
development, epithelial cell growth, carcinogenesis, and and hydrophobic patches predict potential TBRII bind-
ing sites.immune regulation [1]. TGF- is considered an essential
component in the regulation of the immune system [2].
Structurally, TGF-belongs to a superfamily of homol-
Results and Discussionogous growth factors that share at least 25% sequence
identity in their mature amino acid sequence. There are
Structure Solution26 known mammalian TGF- superfamily members and
The crystals belong to space group P212121 with cellvarious other nonmammalian superfamily members.
dimensions a  35.5, b  40.7, and c  76.2 A˚, withThese include activin, bone morphogenic protein (BMP),
one monomer of TBRII in each asymmetric unit. Thegrowth and differentiation factor (GDF), nodal, dorsalin,
structure of the TBRII ectodomain was solved by theMu¨llerian inhibiting substance (MIS), inhibin, and glial
multiwavelength anomalous dispersion (MAD) methodcell-derived neurotrophic factor (GDNF). Based on amino
using an HgCl2 derivative crystal. The electron densityacid sequence homology and functional properties, the
map calculated from the MAD phases was of good qual-TGF-superfamily receptors are divided into two branches,
ity and automatically traced by the ARP/wARP programthe type I and type II receptors. In mammals, there are
(Figure 1) [12]. The structure was refined to 1.1 A˚ resolu-seven known type I receptors and five known type II recep-
tion with a final Rcryst of 15.6% (Rfree  16.6%; Table 1).tors. The type I receptors have a higher level of amino
The refined model contains TBRII residues 26–131, aacid sequence homology to each other than do the type
well-defined glycerol molecule, and 176 water mole-II receptors, especially within the kinase domain [1].
cules. TBRII C-terminal residues 132–136 were disor-In vivo, TGF- binds to the cell surface receptor TBRII,
dered.
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between the 1 and 1″ strands exist exclusively in
TBRII.
Structural Homologs
The structure of TBRII and the previously published
structures of ActRII and BRIA could be superimposed
onto each other with root-mean-square deviations of
1.6 A˚ between TBRII and ActRII (62 C atoms), 2.4 A˚
between TBRII and BRIA (40 C atoms), and 2.5 A˚ be-
tween ActRII and BRIA (54 C atoms) (Figure 4). The
three longest  strands, 3, 4, and 6, which are part
of the larger  sheet, overlay well among all three struc-
tures (Figure 4). The most striking difference between
the TBRII and both the ActRII and BRIA structures is
located in their first finger. Finger one in the TBRII struc-
ture is significantly longer than the corresponding coun-
terparts in the ActRII and BRIA structures. It contains
18 residues (Asp 32–Ser 49), whereas the same region
has 11 (Asn 15–Gln 25), and 10 (Gly 42–Asn 51) residues
in ActRII and BMP, respectively. Structurally, the bottom
of the first finger, the 1 and 2 strands, lies in a similar
position for all three structures. The difference occurs
at the top of the first finger, where TBRII contains two
antiparallel  strands (1 and 1″) linked together by
two unique disulfide bonds Cys 31-Cys 48 and Cys 38-
Cys 44. In this position, ActRII contains an  helix which
points in the direction opposite to that of the 1/1″
strands of TBRII (Figure 4A). The distance between the
tips of the first fingers in the TBRII and ActRII structures
is about 30 A˚. The top part of finger one in BRIA is formed
by a loop that bends even further down compared to
the similar part of the ActRII structure (Figure 4C). The
spatial difference between ActRII and BRIA in this part
of the structure is 11 A˚. Moreover, the BRIA structure
Figure 1. Representative Section of Experimental Electron Density
contains a disulfide bond, which is characteristic for all
The map is calculated with solvent-flattened MAD phases, con-
type I, but is not found in type II, receptors (Figure 3).toured at 1.0  level. The refined atomic model of the TBRII ectodo-
The structure of the BMP-2/BRIA complex revealed thatmain is shown in stick representation.
finger one of BRIA is involved in the binding of its ligand
BMP-2. Therefore, it is plausible to suggest that the role
of this disulfide bond in finger one of type I receptorsGeneral Architecture
The overall structure of the TBRII ectodomain consists is to restrict the flexibility of the top part of the finger
and to bring it into the optimal position for ligand binding.of two antiparallel  sheets. Strands 2, 1, 4, 3, 6,
and 5 form the larger sheet, while strands 1, 1″, The 1 and 1″ strands of TBRII contact the upper
portion of finger two (3 and 4 strands). All three recep-and 7 form the smaller sheet (Figure 2). The TBRII
structure has a three-finger toxin fold similar to some tors overlay well in finger two. The only significant differ-
ence occurs in the upper portion of finger two, whichsnake venom neurotoxins, which is characteristic for
proteins having a common pattern of eight cysteines is noticeable when TBRII and ActRII structures are su-
perimposed (Figure 4A). The upper portion of finger twoforming four disulfide bonds. The first finger contains a
bend with the first portion formed by strands 1 and is flatter in TBRII compared to the inward bending ActRII.
This results in the corresponding loops of finger two in2, and the second by strands 1 and 1″. Strands 3
and 4 form the second finger, while strands 5 and 6 TBRII and ActRII being separated by 10 A˚. The same
loop is disordered in the structure of BRIA/BMP-2form the third finger.
TBRII contains four disulfide bonds conserved among complex.
Two longer antiparallel  strands 5 and 6 form thethe type II TGF- receptor superfamily and two disulfide
bonds unique to TBRII (Figure 3). The conserved disul- third finger in the structure of TBRII. They run closer to
each other compared to the structure of ActRII, wherefide bonds include Cys 28-Cys 61 between the 1 and
3 strands, Cys 54-Cys 78 between the 2 and 4 the corresponding strands are shorter and more di-
verged. The structure of BRIA lacks the 5 strand com-strands, Cys 98-Cys 113 between the 5 and 6 strands,
and Cys 115-Cys 120 between the 6 strand and the pletely. Instead, it has a long loop that connects the
short 3 helix to the 6 strand. Another unique featureloop between the6 and7 strands. The disulfide bonds
Cys 31-Cys 48 between the 1 strand and the loop of TBRII is the absence of a conserved disulfide bond
observed in other type I and type II receptors. This con-between the 1″ and 2 strands, and Cys 38-Cys 44
Structure of TGF- Type II Receptor
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Table 1. Data Collection, Phasing, and Refinement Statistics
Native Hg (remote) Hg (peak) Hg (edge)
Data Collection
Wavelength (A˚) 1.0092 1.0011 1.0076 1.0092
Resolution limit (A˚) 1.05 1.44 1.30 1.34
Unique reflections 45,991 (2,277)a 33,021 (2,975) 47,303 (3,472) 41,063 (3,461)
Redundancy 8.5 (3.9) 2.2 (2.2) 2.4 (1.5) 2.2 (1.7)
Completeness (%) 87.9 (44.3) 87.6 (79.5) 92.1 (67.6) 87.5 (73.1)
Rsym (%)b 3.5 (48.8) 3.8 (35.7) 2.9 (24.3) 3.0 (31.3)
I/(I) 56.5 (2.8) 19.4 (1.8) 27.6 (2.7) 26.6 (2.2)
Phasing (36–1.4 A˚)
Mean figure of merit 0.62
RCullisc 0.69 0.44 0.48
Phasing powerd 1.48 3.70 3.47
Refinement
Resolution (A˚) 36–1.05
Number of reflections 43,635
Number of protein atoms 828
Number of solvent atoms 184
Rcryst (%) 15.6 (29.2)
Rfree (%)e 16.6 (29.0)
Mean B factor (A˚2) 12
Wilson B factor (A˚2) 8.0
Rmsd bond lengths (A˚) 0.007
Rmsd bond angles () 1.48
Ramachandran statisticsf 88.7% 11.3% 0.0% 0.0%
a Values for highest resolution shells 1.09–1.05 (native), 1.49–1.44 (remote), 1.35–1.30 (peak), and 1.39–1.34 (edge) A˚ are given in brackets.
b Rsym  100 	 
|Ih  Ih|/
Ih, where Ih is the mean intensity of multiple measurements of symmetry equivalent reflections.
c RCullis  rms (E)/rms (F), where E is the phase-integrated lack of closure and F is the dispersive or anomalous difference.
d Phasing power  rms (FH)/rms (E), where FH is the calculated heavy atom structure factor.
e Rfree was calculated using test set of 5%.
f Percentages of residues are shown for the most favored region, additional allowed region, generously allowed region, and disallowed region
of the Ramachandran plot.
served disulfide is located between the 3 helix and the
6 strand (Cys 66-Cys 85 in ActRII and Cys 87-Cys 101
in BRIA). At this conserved disulfide location, TBRII has
a hydrogen bond between Asp 92 and Ser 114 (Figures
4A and 4B). In contrast, BRIA, like other mammalian
type I receptors, lacks the Cys 98-Cys 113 disulfide
bond (TBRII numbering) that connects the 5 and 6
strands in type II structures (Figure 4B).
Sequence Homologs
There are common features in the pattern of disulfide
bonds among members of the mammalian TGF- super-
family type I and type II receptors (Figure 3). These
include three structurally identical disulfide bonds Cys
28-Cys 61, Cys 54-Cys 78, and Cys 115-Cys 120 (TBRII
numbering) that are conserved among all mammalian
type I and type II receptors. TBRII lacks a fourth disulfide
bond between the3 and the6 strand that is conserved
among all other mammalian receptors. Here, instead of
the cysteines observed in other sequences, TBRII has
Asp 92 and Ser 114 in the corresponding positions.
These residues form a hydrogen bond of 2.7 A˚ between
the O1 atom of Asp 92 and the O atom of Ser 114.
Compared to mammalian type I receptors, all mamma-
lian type II receptors have an additional disulfide bond
Figure 2. Ribbon Drawing of the TBRII Ectodomain Cys 98-Cys 113 that connects the 5 and 6 strands.
All  strands are marked in accordance with the sequence alignment In addition to these conserved disulfide bonds, there
in Figure 3. The disulfide bonds common to TBRII and ActRII are in are distinct differences in receptor disulfide bond archi-
yellow (C28-C61, C54-C78, C98-C113, and C115-C120). The disul-
tecture. TBRII has two unique disulfide bonds, Cys 31-fide bonds unique to TBRII are in red (C31-C48 and C38-C44). This
Cys 48 and Cys 38-Cys 44, located in finger one thatfigure and the subsequent ribbon drawings were prepared using
the programs MOLSCRIPT [26] and Raster3D [27]. bridge together opposite sides of the upper portion of
Structure
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Figure 3. The Amino Acid Sequences of TGF-, Activin, and BMP Receptor Type I and II Ectodomains
Gaps are indicated with (.). The numbering is consistent with the mature sequence of TBRII except for the engineered mutations T26A and
K97T. The secondary structure elements of TBRII are illustrated as arrows for  strands and as cylinders for  helices. These elements
correspond to the following TBRII residues: 1 (26–31), 1 (34-40), 1″ (42–46), 2 (50–54), 3 (60–68), 4 (71–79), 5 (96–104), 6 (108–116),
7 (122–127), 1 (56–59), 2 (80–83), and 3 (90–93). The BRIA residues involved in ligand-receptor interactions are highlighted in gray. The
cysteine residues are highlighted in yellow. Disulfide bridges that are common among all mammalian receptors are given in black, one unique
to mammalian type II receptors in gray, two unique to TBRII in cyan, and one characteristic of mammalian type I receptors in pink. All
sequences are human except for ActRII (mouse).
the finger (Figures 2 and 4). Mammalian type I receptors Instead of bridging opposite sides of finger one (like in
TBRII), this disulfide bond connects cysteine residueshave a conserved disulfide bond, Cys 40-Cys 44 (BRIA
numbering), which is also located in finger one. How- that are only 3 residues apart in the BRIA structure and
located on the same side of the finger. As it was pointedever, the placement and architecture of this disulfide
bond is different from that of TBRII, Cys 31-Cys 48. out above, a possible function of this disulfide bond,
Figure 4. Structural Comparison of Ectodomains of Some Members of the TGF- Superfamily
(A) Structural comparison between TBRII (cyan) and ActRII (gray) ectodomains. The numbering is consistent with the mature sequence of
TBRII. Disulfide bridges of TBRII (C28-C61, C31-C48, C38-C44, C54-C78, C98-C113, and C115-C120) are blue. Disulfide bridges of ActRII
(C11-C41, C31-C59, C66-C85, C72-C84, and C86-C91) are yellow. The coordinates for the ActRII ectodomain are taken from Protein Data
Bank entry 1bte.
(B) Structural comparison between TBRII (cyan) and BRIA (pink) ectodomains. The numbering is consistent with the mature sequence of
TBRII. Disulfide bridges of TBRII are blue. Disulfide bridges of BRIA (C38-C59, C40-C44, C55-C77, C87-C101, and C102-C107) are red. The
coordinates for the BRIA ectodomain are taken from Protein Data Bank entry 1es7.
(C) Structural comparison between ActRII (gray) and BRIA (pink) ectodomains. The numbering is consistent with the mature sequence of
ActRII. Disulfide bridges of ActRII are yellow and of BRIA are red.
Structure of TGF- Type II Receptor
917
Figure 5. Surface Representation of Charge Distribution and Hydrophobic Patches on TBRII
(A) Orientation of the molecule corresponds to that of Figures 2 and 4.
(B) Molecule is rotated about 180 degrees around the vertical axis compared to (A).
(C) Molecule is rotated about 90 degrees around the horizontal axis compared to (A). Ribbon drawings in the lower panel are given as an
orientation reference. Hydrophobic patches are colored yellow. Positive and negative charges are colored blue and red, respectively.
which is conserved among the mammalian type I recep- the flexibility of the loop on the tip of finger one and bring
this loop into the optimal position for ligand binding. Thistors, could be to restrict the movement of finger one
and bring it into the optimal position for ligand binding. suggests that other mammalian type I receptors will
have a finger one similar to BRIA in overall shape andAn examination of the type I and type II receptor amino
acid sequences from three members of the mammalian position.
The absence of the Cys 98-Cys 113 disulfide bondTGF- superfamily provides predictive information
about the structures of BRII, TBRI, and ActRI (Figure 3). (TBRII numbering) in BRIA may be linked to the absence
of the 5 strand in the structure of BRIA. Therefore,The length of the first finger region in the BRII sequence
is exactly the same as in the TBRII sequence, suggesting other mammalian type I receptor structures might have
the same long loop running parallel to the 6 strand andthat BRII will have a secondary structure similar to the
1/1″ antiparallel  strands of finger one in TBRII. The connecting the short helix 3 to the 6 strand.
In summary, the results of structure analysis and se-absence of TBRII finger one disulfide bonds (Cys 31-
Cys 48 and Cys 38-Cys 44; TBRII numbering) in BRII quence alignment suggest that the overall fold of the
BRII structure will be similar to TBRII, with two antiparal-might be compensated for by salt bridges/hydrogen
bonds between Lys 31 and Glu 48 and between Asp 37 lel  strands in the upper part of finger one forming a
core of the second short antiparallel  sheet. The TBRIand Arg 44 residues (TBRII numbering; Figure 3) located
around respective TBRII cysteines in the sequence and ActRI structures would be predicted to be similar
to their type I receptor counterpart, BRIA.alignment (Figure 3).
This same finger one region is significantly (11–14
residues) shorter than the corresponding region of TBRII Putative Binding Sites of TBRII
Upon cell surface activation, TGF- forms a ternary com-and BRII for all mammalian type I receptors. In addition,
mammalian type I receptors have a conserved disulfide plex with both type I and type II receptors. The type II
receptor, owing to its nanomolar affinity to TGF-1 (databond, Cys 40-Cys 44 (BRIA numbering), that may restrict
Structure
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not shown), presumably serves as the primary recruiting ActRII in this region, including F42A, W60A, and F83A,
have been produced and result in a loss in receptorreceptor for the ligand. The type I receptor, in contrast,
lacks appreciable affinity to TGF- in the absence of binding to activin and inhibin [16]. The same region of
TBRII, however, is completely covered by its long firstthe type II receptor and is likely recruited to the TBRII/
TGF- heterodimeric complex to form the final trimeric finger and is no longer surface exposed. This difference
between TBRII and ActRII may contribute to their uniquecomplex. The unique role of TBRII in bridging the ternary
complex formation suggests two binding surfaces, one ligand recognition.
with TGF- and another with TBRI. Based on the current
TBRII structure and the available structures of ActRII Biological Implications
and BRIA/BMP-2 complex, the putative ligand and type
I receptor binding regions are proposed here. In general, TGF- inhibits cell growth, and mutations in
Structural analysis of BRIA/BMP-2 complex [11] re- the TBRII are associated with cancer. Most sporadic
vealed predominantly hydrophobic interactions at the colon and gastric cancers have an inactive TBRII, and
binding interface. Previous studies have shown that mutations in the receptor have also been identified in T
large surface-exposed hydrophobic patches often con- cell lymphoma, and head and neck carcinomas [1].
stitute binding surfaces [13], as seen in the human Given the wide range of biological functions, design of
growth hormone-growth hormone receptor complex blocking agents that distinguish between various TGF-
[14]. Analysis of the charged versus hydrophobic resi- receptors could have important pharmacological impli-
due distribution on the TBRII surface reveals three ex- cations. Structural differences between different mem-
tensive hydrophobic patches that could be candidate bers of the TGF- receptor superfamily will aid in the
TGF- and TBRI binding sites (Figure 5). The largest design of potential therapeutic agents. The striking dif-
surface patch, approximately 700 A˚2 in size, is located ference in the structure of TBRII compared to ActRII
on the “bottom” of TBRII (in the area of conserved disul- and BRIA is structure and location of the 1/1″ strand
fide bonds). It contains the N termini of the 1, 3, and at the top of finger one. Sequence homology suggests
5 strands, the C termini of the 2, 4, and 6 strands, that this structural feature will be more typical of most
as well as the 1, 2, and 3 helices (Figure 5C). As type II receptors rather than the  helix in finger one of
TBRII possesses higher binding affinity for TGF- than the ActRII structure. This information could be poten-
for TBRI, it is tempting to speculate that this largest tially useful in designing agents that specifically block
surface patch corresponds to the binding site for TGF-. interactions between type II receptors and their ligands
This region contains a unique disulfide bond on the first or between type II and type I receptors.
finger and the presence of the 5 strand, constituting
the major structural differences between the type I and
Experimental Procedurestype II receptors, which may reflect their differences in
ligand binding (Figures 3 and 4). The involvement of this Sample Preparation and Crystallization
surface patch in TGF- binding is supported by the Human TBRII (T26A/K97T) residues 26–136 was expressed in E.
coli as inclusion bodies and refolded as previously described [17].binding studies of TBRII deletion mutants [15]. It was
Crystallization was carried out using the vapor diffusion methodfound through a series of TBRII deletion mutants that
with drops containing TBRII ectodomain (20 mg ml1) and 30% PEGonly the following mutants disrupt the binding of TGF-
2000 with 0.1 M Na citrate (pH 5.0) as described in details elsewhere
1 to the receptor: F35-T37, N40-K42, and M45-
[18].
N47, which are located in the first finger, and E55-
P57, D80-K82, and S95-T97, which are in the largest
Data Collection and Structure Determination
hydrophobic patch. The next prominent hydrophobic After a brief soaking in precipitant solutions containing 25% glycerol,
patch, a possible site for TBRI binding, is about 500 A˚2 crystals were flash frozen at 100 K. X-ray diffraction data from single
in size and is located on the “back side” of the molecule crystals were collected using an ADSC Quantum IV CCD detector at
the X9B beamline of the National Synchrotron Light Source (NSLS),(Figure 5B). It includes the 2 and 4 strands, a tip of
Brookhaven National Laboratory and processed with HKL2000 [19].the2 helix, and a loop connecting the2 and3 helices.
A MAD data set was collected from crystals soaked in HgCl2 at theInterestingly, this region is also topologically equivalent
X9B beamline (NSLS). Three Hg sites were found by SOLVE [20].
to the BMP-2 binding site on BRIA. The third patch is After density modification, including solvent flattening, the electron
in the “front” of the molecule. It is the smallest patch density was traced using the ARP/wARP autotracing program [12].
(about 250 A˚2 ) among the three and is also more frag- Model adjustments and rebuilding were done using the program O
[21]. The initial positional and individual B factor refinement wasmented than the previous two patches (Figure 5A). It
carried out using a maximum likelihood target function of CNS v1.0comprises the N terminus of the 1″ strand, the C termi-
[22]. The final anisotropic refinement with maximum likelihood targetnus of the 7 strand, and a small portion of the5 strand.
function was carried out by REFMAC5 [23] from the CCP4 programIn addition, the location of the third patch is consistent
suite [24].
with it being orientated toward the plasma membrane,
thus making it unlikely to be involved in either TGF- or
Acknowledgmentstype I receptor binding.
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